AUPH Stock Summary and Trading Ideas (Aurinia Pharmaceuticals - Common Shares | NASDAQ:AUPH)

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Aurinia Pharmaceuticals - Common Shares trades on the NASDAQ stock market under the symbol AUPH.

As of June 25, 2026, AUPH stock price declined to $17.55 with 2,028,807 million shares trading.

AUPH has a beta of 0.06, meaning it tends to be less sensitive to market movements. AUPH has a correlation of 0.00 to the broad based SPY ETF.

AUPH has a market cap of $2.26 billion. This is considered a Mid Cap stock.

Last quarter Aurinia Pharmaceuticals - Common Shares reported $78 million in Revenue and $.25 earnings per share. This beat revenue expectation by $642,032 and exceeded earnings estimates by $.06.

In the last 3 years, AUPH traded as high as $19.25 and as low as $4.71.

The top ETF exchange traded funds that AUPH belongs to (by Net Assets): IWM, IWO, IBB, JSMD, VTWO.

AUPH has outperformed the market in the last year with a price return of +118.0% while the SPY ETF gained +22.3%. AUPH has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +23.5% and +12.1%, respectively, while the SPY returned +12.7% and +1.5%, respectively.

AUPH support price is $18.09 and resistance is $19.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AUPH shares will trade within this expected range on the day.